Prostate cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortium
Background Screening and diagnosis of prostate cancer (PCa) is hampered by an inability to predict who has the potential to develop fatal disease and who has indolent cancer. Studies have identified multiple genetic risk loci for PCa incidence, but it is unknown whether they could be used as biomark...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
2014
|
| _version_ | 1797051524518510592 |
|---|---|
| author | Shui, I Lindström, S Kibel, A Berndt, S Campa, D Gerke, T Penney, K Penney, K Albanes, D Berg, C Bueno-De-Mesquita, H Bueno-De-Mesquita, H Bueno-De-Mesquita, H Chanock, S Chanock, S Crawford, E Diver, W Gapstur, S Gaziano, J Gaziano, J Gaziano, J Giles, G Giles, G Henderson, B Hoover, R |
| author_facet | Shui, I Lindström, S Kibel, A Berndt, S Campa, D Gerke, T Penney, K Penney, K Albanes, D Berg, C Bueno-De-Mesquita, H Bueno-De-Mesquita, H Bueno-De-Mesquita, H Chanock, S Chanock, S Crawford, E Diver, W Gapstur, S Gaziano, J Gaziano, J Gaziano, J Giles, G Giles, G Henderson, B Hoover, R |
| author_sort | Shui, I |
| collection | OXFORD |
| description | Background Screening and diagnosis of prostate cancer (PCa) is hampered by an inability to predict who has the potential to develop fatal disease and who has indolent cancer. Studies have identified multiple genetic risk loci for PCa incidence, but it is unknown whether they could be used as biomarkers for PCa-specific mortality (PCSM). Objective To examine the association of 47 established PCa risk single-nucleotide polymorphisms (SNPs) with PCSM. Design, setting, and participants We included 10 487 men who had PCa and 11 024 controls, with a median follow-up of 8.3 yr, during which 1053 PCa deaths occurred. Outcome measurements and statistical analysis The main outcome was PCSM. The risk allele was defined as the allele associated with an increased risk for PCa in the literature. We used Cox proportional hazards regression to calculate the hazard ratios of each SNP with time to progression to PCSM after diagnosis. We also used logistic regression to calculate odds ratios for each risk SNP, comparing fatal PCa cases to controls. Results and limitations Among the cases, we found that 8 of the 47 SNPs were significantly associated (p < 0.05) with time to PCSM. The risk allele of rs11672691 (intergenic) was associated with an increased risk for PCSM, while 7 SNPs had risk alleles inversely associated (rs13385191 [C2orf43], rs17021918 [PDLIM5], rs10486567 [JAZF1], rs6465657 [LMTK2], rs7127900 (intergenic), rs2735839 [KLK3], rs10993994 [MSMB], rs13385191 [C2orf43]). In the case-control analysis, 22 SNPs were associated (p < 0.05) with the risk of fatal PCa, but most did not differentiate between fatal and nonfatal PCa. Rs11672691 and rs10993994 were associated with both fatal and nonfatal PCa, while rs6465657, rs7127900, rs2735839, and rs13385191 were associated with nonfatal PCa only. Conclusions Eight established risk loci were associated with progression to PCSM after diagnosis. Twenty-two SNPs were associated with fatal PCa incidence, but most did not differentiate between fatal and nonfatal PCa. The relatively small magnitudes of the associations do not translate well into risk prediction, but these findings merit further follow-up, because they may yield important clues about the complex biology of fatal PCa. Patient summary In this report, we assessed whether established PCa risk variants could predict PCSM. We found eight risk variants associated with PCSM: One predicted an increased risk of PCSM, while seven were associated with decreased risk. Larger studies that focus on fatal PCa are needed to identify more markers that could aid prediction. © 2013 European Association of Urology. |
| first_indexed | 2024-03-06T18:20:42Z |
| format | Journal article |
| id | oxford-uuid:062f1042-e067-4938-9c79-78a52c18afe2 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T18:20:42Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:062f1042-e067-4938-9c79-78a52c18afe22022-03-26T09:01:18ZProstate cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortiumJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:062f1042-e067-4938-9c79-78a52c18afe2Symplectic Elements at Oxford2014Shui, ILindström, SKibel, ABerndt, SCampa, DGerke, TPenney, KPenney, KAlbanes, DBerg, CBueno-De-Mesquita, HBueno-De-Mesquita, HBueno-De-Mesquita, HChanock, SChanock, SCrawford, EDiver, WGapstur, SGaziano, JGaziano, JGaziano, JGiles, GGiles, GHenderson, BHoover, RBackground Screening and diagnosis of prostate cancer (PCa) is hampered by an inability to predict who has the potential to develop fatal disease and who has indolent cancer. Studies have identified multiple genetic risk loci for PCa incidence, but it is unknown whether they could be used as biomarkers for PCa-specific mortality (PCSM). Objective To examine the association of 47 established PCa risk single-nucleotide polymorphisms (SNPs) with PCSM. Design, setting, and participants We included 10 487 men who had PCa and 11 024 controls, with a median follow-up of 8.3 yr, during which 1053 PCa deaths occurred. Outcome measurements and statistical analysis The main outcome was PCSM. The risk allele was defined as the allele associated with an increased risk for PCa in the literature. We used Cox proportional hazards regression to calculate the hazard ratios of each SNP with time to progression to PCSM after diagnosis. We also used logistic regression to calculate odds ratios for each risk SNP, comparing fatal PCa cases to controls. Results and limitations Among the cases, we found that 8 of the 47 SNPs were significantly associated (p < 0.05) with time to PCSM. The risk allele of rs11672691 (intergenic) was associated with an increased risk for PCSM, while 7 SNPs had risk alleles inversely associated (rs13385191 [C2orf43], rs17021918 [PDLIM5], rs10486567 [JAZF1], rs6465657 [LMTK2], rs7127900 (intergenic), rs2735839 [KLK3], rs10993994 [MSMB], rs13385191 [C2orf43]). In the case-control analysis, 22 SNPs were associated (p < 0.05) with the risk of fatal PCa, but most did not differentiate between fatal and nonfatal PCa. Rs11672691 and rs10993994 were associated with both fatal and nonfatal PCa, while rs6465657, rs7127900, rs2735839, and rs13385191 were associated with nonfatal PCa only. Conclusions Eight established risk loci were associated with progression to PCSM after diagnosis. Twenty-two SNPs were associated with fatal PCa incidence, but most did not differentiate between fatal and nonfatal PCa. The relatively small magnitudes of the associations do not translate well into risk prediction, but these findings merit further follow-up, because they may yield important clues about the complex biology of fatal PCa. Patient summary In this report, we assessed whether established PCa risk variants could predict PCSM. We found eight risk variants associated with PCSM: One predicted an increased risk of PCSM, while seven were associated with decreased risk. Larger studies that focus on fatal PCa are needed to identify more markers that could aid prediction. © 2013 European Association of Urology. |
| spellingShingle | Shui, I Lindström, S Kibel, A Berndt, S Campa, D Gerke, T Penney, K Penney, K Albanes, D Berg, C Bueno-De-Mesquita, H Bueno-De-Mesquita, H Bueno-De-Mesquita, H Chanock, S Chanock, S Crawford, E Diver, W Gapstur, S Gaziano, J Gaziano, J Gaziano, J Giles, G Giles, G Henderson, B Hoover, R Prostate cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortium |
| title | Prostate cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortium |
| title_full | Prostate cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortium |
| title_fullStr | Prostate cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortium |
| title_full_unstemmed | Prostate cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortium |
| title_short | Prostate cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortium |
| title_sort | prostate cancer pca risk variants and risk of fatal pca in the national cancer institute breast and prostate cancer cohort consortium |
| work_keys_str_mv | AT shuii prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT lindstroms prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT kibela prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT berndts prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT campad prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT gerket prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT penneyk prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT penneyk prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT albanesd prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT bergc prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT buenodemesquitah prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT buenodemesquitah prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT buenodemesquitah prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT chanocks prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT chanocks prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT crawforde prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT diverw prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT gapsturs prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT gazianoj prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT gazianoj prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT gazianoj prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT gilesg prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT gilesg prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT hendersonb prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium AT hooverr prostatecancerpcariskvariantsandriskoffatalpcainthenationalcancerinstitutebreastandprostatecancercohortconsortium |